Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study

Liver Transplantation

Volumn 12, Issue 9, 2006, Pages 1342-1346

  Dumortier, Jérôme ^a   Gagnieu, Marie Claude ^a   Salandre, Janine ^a   Guillaud, Olivier ^a   Guillem, Philipe ^a   Adham, Mustapha ^a   Boillot, Olivier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; BLOATING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DYSPEPSIA; ENTERIC COATED TABLET; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; SYMPTOM; VOMITING;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TABLETS, ENTERIC-COATED;

EID: 33748804924     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20792     Document Type: Article

References (23)

1. Fisher RA, Ham JM, Marcos A, Shiffman ML, Luketic VA, Kimball PM, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Tnansplantation 1998;66:1616-1621.
2. Wiesner RH, Shorr, JS, Steffen BJ, Chu AH, Gordon RD, Lake JR Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005;11:750-759.
3. Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 2001;33:3238-2340.
4. Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother 2003;37:1685-1693.
5. Behrend M, Braun F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs 2005;65:1037-1050.
6. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, et al. Enteric-coated mycopherrolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004;4:231-236.
7. Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004;4:237-243.
8. Behrend M. Mycophenolate mofetil (Cellcept). Expert Opin Investig Drugs 1998;7:1509-1519.
9. Jain A, Kashyap R, Dodson F, Kramer D, Hamad I, Khan A, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation 2001;72:1091-1097.
10. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001:7:442-450.
11. Manzia TM, De Liguori Carino N, Orlando G, Toti L, De Luca L, D'Andria D, et al. Use of mycopherrolate mofetil in liver transplantation: a literature review. Transplant Proc 2005;37:2616-2617.
12. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001;24:645-663.
13. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002; 13:277-287.
14. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: Etiology and management. Liver Transpl 2005; 11:881-890.
15. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14:2381-2386.
16. Pelletier RP, Akin B, Henry ML, Bumgardner GL, Elkhammas EA, Rajah A, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17:200-205.
17. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004;17:609-616. Epub 2004 Oct 29.
18. Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, et al. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. Transplant Proc 2004; 36:524S-527S.
19. Kamar N, Oufroukhi L, Faure P, Ribes D, Cointault O, Lavayssiere L, et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 2005;20:2231-2236.
20. Maes BD, Dalle I, Geboes K, Oellerich M, Armstrong VW, Evenepoel P, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003;75:665-672.
21. Pietruck F, Suwelack B, Ivens K, Po-Huang L, Massart P, Kirchherr B, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: results of a prospective international multi-center trial. Transplant Int 2005;18(s1):51.
22. Vela C, Canet S, Mourad G. Switch from mycophenolate mofetil to mycophenolate mofetil enteric coated in transplant renal recipients is an alternative in serious gastrointestinal intolerance. Transplant Int 2005;18(s1):115.
23. Mulgaonkar S, Haller H, Pefaur J, Ambühl P, Faull R, Arns W. Positive impact on health related quality of life in patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium due to gastrointestinal complaints. Transplant Int 2005;18(s1):24.